XyloCor Therapeutics (XyloCor), a clinical‑stage biopharmaceutical company developing novel gene therapies for cardiovascular disease, has completed a $67.5 million Series B financing round. New investor Jeito Capital, a global private equity fund, led the Series B financing round which also included existing institutional investors EQT, Fountain Healthcare Partners, and Lumira Ventures.

The investment will support a randomised, double‑blind Phase 2b clinical trial (EXACT‑2) of XC001 (encoberminogene rezmadenovec), in refractory angina, using a new non‑surgical method of endocardial administration via a novel injection catheter. The financing will also fund a second randomised, double‑blind Phase 2 trial of XC001 as an adjunctive treatment to coronary artery bypass graft surgery (CABG). XC001 offers a new therapeutic approach for debilitating and chronic conditions.